Global Kidney Cancer Therapeutics and Diagnostics Market Size, Status and Forecast 2020-2029 (Includes Business Impact of COVID-19)

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Kidney Cancer Therapeutics and Diagnostics market.

Trusted Business Insights presents an updated and Latest Study on Kidney Cancer Therapeutics and Diagnostics Market. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Kidney Cancer Therapeutics and Diagnostics market during the forecast period.
It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Kidney Cancer Therapeutics and Diagnostics Market Size, Status and Forecast 2020-2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Kidney Cancer Therapeutics and Diagnostics Market

The occurrence of kidney cancer has increased in the recent years. Excessive smoking, rise in obesity because of sedentary life routines and increased consumption of alcohol are some of the causes of kidney cancer. The most common type of cancer is Renal Cell Carcinoma (RCC). Immunotherapies or targeted therapies are the most common prescribed treatments for kidney cancer.

Bladder cancer is the tenth most common cancer worldwide and the sixth most common cancer in the US. In 2018, there were over half a million new cases of bladder cancer diagnosed, with around 200,000 deaths from the disease globally. In the US, an estimated 80,470 cases of bladder cancer were diagnosed in 2019, with around 12,500 locally advanced or metastatic cases presented annually. UC accounts for about 90% of all bladder cancers. UC becomes harder to treat as it advances, spreading through the layers of the bladder wall.

In 2018, the global Kidney Cancer Therapeutics and Diagnostics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025. This report focuses on the global Kidney Cancer Therapeutics and Diagnostics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Kidney Cancer Therapeutics and Diagnostics development in United States, Europe and China.

Market Segmentation, Outlook & Regional Insights: Kidney Cancer Therapeutics and Diagnostics Market

Segmentation by Product Type: Breakdown of data from year 2014 to 2020 and forecast until 2029:

  • Cystoscopy
  • Biopsy
  • Intravenous Pyelogram
  • CT Scan
  • Kidney Ultrasound
  • Others

Segmentation by Application: Breakdown of data from year 2014 to 2020 and forecast until 2029:

  • Hospitals
  • Pharmaceutical Labs
  • Genomics Laboratories
  • Others

Market segment by Regions/Countries, this report covers

  • United States
  • Europe
  • China
  • Japan
  • Southeast Asia
  • India
  • Central & South America

Key Players, Recent Developments & Sector Viewpoints: Kidney Cancer Therapeutics and Diagnostics Market

  • Bayer
  • Hoffmann La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Abbott Laboratories
  • Amgen
  • Genentech
  • Cerulean Pharma
  • Seattle Genetics

In Jun 2020, FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma. First and only FDA-approved immunotherapy to demonstrate a significant overall survival benefit in the first-line setting in a Phase III study. Priority review completed under FDAs Real-Time Oncology Review (RTOR) pilot program, following receipt of Breakthrough Therapy Designation. EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.For patients that do not progress on platinum-containing chemotherapy, BAVENCIO is administered as a first-line maintenance treatment until disease progression or unacceptable toxicity.

The FDA previously approved BAVENCIO under the accelerated approval program in 2017 for the treatment of patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, based on tumor response rate and duration of response. Continued approval was contingent upon verification of clinical benefit, which was demonstrated in JAVELIN Bladder 100. The FDA has now converted the accelerated approval to full approval.

This approval for BAVENCIO, has the opportunity to fundamentally shift the standard of care in the first-line setting of advanced bladder cancer. The focus will be to work closely with the GU community to ensure that this novel and potentially life-changing treatment paradigm is rapidly integrated into clinical practice.

The alliance is committed to providing patient access and reimbursement support through its CoverOne® program to patients who have been prescribed BAVENCIO. This program provides a spectrum of patient access and reimbursement support services intended to help US patients prescribed BAVENCIO receive appropriate access.

Key Insights Covered: Exhaustive Kidney Cancer Therapeutics and Diagnostics Market
1. Market size (sales, revenue and growth rate) of Kidney Cancer Therapeutics and Diagnostics industry.
2. Global major manufacturers’ operating situation (sales, revenue, growth rate and gross margin) of Kidney Cancer Therapeutics and Diagnostics industry.
3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Kidney Cancer Therapeutics and Diagnostics industry.
4. Market size (sales, revenue) forecast by regions and countries from 2021 to 2026 of Kidney Cancer Therapeutics and Diagnostics industry.

Research Methodology: Kidney Cancer Therapeutics and Diagnostics Market

  • Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  • Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  • Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.

 

Looking for more? Check out our repository for all available reports on Kidney Cancer Therapeutics and Diagnostics in related sectors.

Quick Read Table of Contents of this Report @ Global Kidney Cancer Therapeutics and Diagnostics Market Size, Status and Forecast 2020-2029 (Includes Business Impact of COVID-19)

Contacts

Trusted Business Insights
Shelly Arnold
Media & Marketing Executive
Email Me For Any Clarifications
Connect on LinkedIn
Click to follow Trusted Business Insights LinkedIn for Market Data and Updates.
US: +1 646 568 9797
UK: +44 330 808 0580